
Raj Tummala

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9632848/publications.pdf Version: 2024-02-01



Ραι Τιιμμαια

#	Article	IF	CITATIONS
1	Trial of Anifrolumab in Active Systemic Lupus Erythematosus. New England Journal of Medicine, 2020, 382, 211-221.	13.9	725
2	Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatology, The, 2019, 1, e208-e219.	2.2	250
3	Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Annals of the Rheumatic Diseases, 2022, 81, 496-506.	0.5	87
4	Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: <i>post-hoc</i> analysis of the Phase IIb MUSE trial of anifrolumab. Annals of the Rheumatic Diseases, 2018, 77, 706-713.	0.5	64
5	Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials. Modern Rheumatology, 2021, 31, 1-12.	0.9	52
6	Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus. Lupus Science and Medicine, 2018, 5, e000284.	1.1	51
7	Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials. Lupus Science and Medicine, 2021, 8, e000464.	1.1	45
8	Longâ€Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open‣abel Extension Study. Arthritis and Rheumatology, 2021, 73, 816-825.	2.9	40
9	Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Annals of the Rheumatic Diseases, 2022, 81, 951-961.	0.5	38
10	Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. Lupus, 2021, 30, 1254-1263.	0.8	36
11	Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials. Lancet Rheumatology, The, 2022, 4, e282-e292.	2.2	34
12	Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. Annals of the Rheumatic Diseases, 2022, 81, 962-969.	0.5	15
13	Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus. Journal of Comparative Effectiveness Research, 2022, 11, 765-777.	0.6	14
14	Treatment with Naloxegol Versus Placebo: Pain Assessment in Patients with Noncancer Pain and Opioidâ€Induced Constipation. Pain Practice, 2018, 18, 505-514.	0.9	12
15	What Does it Mean to be a British Isles Lupus Assessment Group–Based Composite Lupus Assessment Responder? Post Hoc Analysis of 2 Phase 3 Trials. Arthritis and Rheumatology, 2021, 73, 2059-2068.	2.9	12
16	Exposure–response analysis for selection of optimal dosage regimen of anifrolumab in patients with systemic lupus erythematosus. Rheumatology, 2021, 60, 5854-5862.	0.9	11
17	Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus. Rheumatology, 2022, 61, 1900-1910.	0.9	10
18	Study protocol for the international Systemic Lupus Erythematosus Prospective Observational Cohort Study (SPOCS): understanding lupus and the role of type I interferon gene signature. BMJ Open, 2020, 10, e036563.	0.8	8

Raj Tummala

#	Article	IF	CITATIONS
19	Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab. Lancet Rheumatology, The, 2022, 4, e198-e207.	2.2	7
20	Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus Erythematosus. Journal of Clinical Pharmacology, 2022, 62, 1106-1120.	1.0	5
21	The Efficacy and Safety of Anifrolumab in Japanese Patients With Systemic Lupus Erythematosus: TULIP-2 Subanalysis. Modern Rheumatology, 2022, , .	0.9	3
22	Causal cascade of direct and indirect effects of anifrolumab on patient-reported outcomes: structural equation modelling of two Phase 3 trials. Rheumatology, 2022, 61, 4731-4740.	0.9	2